PMS2 and digestive system cancer: If further studies with larger cohorts can prove the clustering of mutations in DNA-repair related genes in MLH1-/PMS2-/MSH6- digestive system cancers, this peculiar immunophenotype could immediately trigger additional NGS-testing for HRR mutations as basis for therapy.